Zim Laboratories Q1 FY27 Results (NSE: ZIMLAB)
Signal: Loss widened
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹0.94 Cr | 31.3% | -10.5% |
| EBIT | ₹-0.02 Cr | N/A | |
| Net profit | ₹-0.04 Cr | N/A | |
| EPS | ₹-0.75 | N/A | |
| EBIT margin | -2.0% |
P&L walk
Revenue surged 31% YoY but gross margin collapsed as raw material cost ratio jumped ~780bps, driving EBITDA margin to 3.7% (down 470bps YoY); elevated depreciation (+10.5% YoY) and finance cost (+10.3% YoY) pushed PBT deep into loss; net loss widened to ₹4.02 Cr from ₹1.87 Cr loss a year ago.
Research and educational content only. Not investment advice.